We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+41.14%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.71B
AUM Growth
-$3.29B
Cap. Flow
-$4.28B
Cap. Flow %
-91.04%
Top 10 Hldgs %
76.49%
Holding
126
New
17
Increased
33
Reduced
15
Closed
22

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$44.9M
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$20.1M
3
BPMC
Blueprint Medicines
BPMC
+$19.9M
4
NKTR icon
Nektar Therapeutics
NKTR
+$15.4M
5
AUTL
Autolus Therapeutics
AUTL
+$13.9M

Top Sells

Rank Stock Value
1
BUFF
Blue Buffalo Pet Products, Inc
BUFF
+$3.48B
2
WW
WW International
WW
+$678M
3
INCY icon
Incyte
INCY
+$25M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$13.1M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 44.73%
2 Healthcare 36.09%
3 Communication Services 0%
4 Consumer Staples 0%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
101
Novavax
NVAX
$1.21B
$670K 0.01%
25,000
– –
ATYR
102
aTyr Pharma
ATYR
$48M
$455K 0.01%
35,714
– –
SNDX icon
103
Syndax Pharmaceuticals
SNDX
$1.7B
$426K 0.01%
60,697
-89,303
-60% -$876K
IMDX
104
Insight Molecular Diagnostics
IMDX
$147M
$383K 0.01%
7,500
– –
CAT icon
105
CALL
Caterpillar
CAT
$371B
– –
-200,000
Closed -$29.5M
CVX icon
106
CALL
Chevron
CVX
$383B
– –
-500,000
Closed -$57M
EDIT icon
107
Editas Medicine
EDIT
$396M
– –
-25,000
Closed -$829K
IBM icon
108
CALL
IBM
IBM
$214B
– –
-627,600
Closed -$92.1M
INCY icon
109
CALL
Incyte
INCY
$25.6B
– –
-550,000
Closed -$45.8M
INCY icon
110
Incyte
INCY
$25.6B
– –
-300,000
Closed -$25M
IQ icon
111
iQIYI
IQ
$1.21B
– –
-750,000
Closed -$11.7M
KURA icon
112
Kura Oncology
KURA
$803M
– –
-100,000
Closed -$1.88M
NBIX icon
113
CALL
Neurocrine Biosciences
NBIX
$18.2B
– –
-100,000
Closed -$8.29M
NERV icon
114
Minerva Neurosciences
NERV
$194M
– –
-37,500
Closed -$1.88M
NG icon
115
NovaGold Resources
NG
$2.51B
– –
-1,000,000
Closed -$4.33M
REGN icon
116
CALL
Regeneron Pharmaceuticals
REGN
$73.3B
– –
-50,000
Closed -$17.2M
SPY icon
117
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$778B
– –
-500,000
Closed -$132M
VRTX icon
118
CALL
Vertex Pharmaceuticals
VRTX
$124B
– –
-100,000
Closed -$16.3M
XBI icon
119
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-500,000
Closed -$43.9M
XOM icon
120
CALL
ExxonMobil
XOM
$655B
– –
-1,000,000
Closed -$74.6M
RDUS
121
DELISTED
Radius Health, Inc.
RDUS
– –
-300,000
Closed -$10.8M
ALXN
122
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-150,000
Closed -$16.7M
PTLA
123
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-100,000
Closed -$3.27M
ACHN
124
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-750,000
Closed -$2.78M
AVXS
125
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-160,000
Closed -$19.8M
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2018 Portfolio in Review

As of Q2 2018, Artal Group held 126 positions worth $4.71B, down 41% from $7.99B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Artal Group withdrew a net $4.28B in Q2 2018, closing 22 positions and reducing 15 holdings. Its most notable exit was Blue Buffalo Pet Products, Inc, an estimated $3.48B position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 45% of assets, up from 23% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, Artal Group opened a new position in Scholar Rock worth $37.4M.

  • Artal Group's largest Q2 2018 buy was Scholar Rock: 2,396,040 shares worth $37.4M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2018, an estimated $20.1M increase.
  • Artal Group's biggest Q2 2018 reduction was WW International, cutting an estimated $678M.
  • Artal Group fully exited Blue Buffalo Pet Products, Inc in Q2 2018, selling an estimated $3.48B.
  • Artal Group's ten largest holdings make up 76% of its $4.71B portfolio in Q2 2018.
  • Artal Group opened 17 new positions and closed 22 in Q2 2018.
  • Artal Group's portfolio value fell 41% quarter-over-quarter to $4.71B.

Based on Artal Group's 13F filing for Q2 2018, filed 10 Aug 2018.